Searchable abstracts of presentations at key conferences in endocrinology

ea0029s22.1 | Pituitary tumorigenesis | ICEECE2012

Molecular mechanisms: the genes involved in pituitary tumorigenesis

Melmed S.

Pituiatry tumors account for about 15% of all intracranial neoplasms. They arise from pituitary cell types due to both cell cycle trophic dysruptions leading to adenomatous growth, as well as a coupling of specific hormone gene over-expression. Thus, both tumor growth characteristics, as well as hormonal excess are the hallmarks of these invariably benign tumors. They may lead to both central compressive features due to mass expansion or invasion, as well as to specific clinic...

ea0021pl2biog | Society for Endocrinology Transatlantic Medal Lecture | SFEBES2009

Society for Endocrinology Transatlantic Medal Lecture

Melmed S

S Melmed, Cedars-Sinai Medical Center, Los Angeles, California, USA. AbstractShlomo Melmed received his medical degree with distinction from the University of Cape Town, School of Medicine in 1970. At Cedars-Sinai since 1980, he is now Senior Vice-President for Academic Affairs, and Dean of the Medical Faculty. He is also Professor and Associate Dean of UCLA School of Medicine.Dr Melmed is a Dip...

ea0008p22 | Cytokines and growth factors | SFE2004

Somatostatin Abrogates GH-Induced Hepatocyte IGF-I Transcription by Inhibiting STAT5b Phosphorylation & Nuclear Translocation

Murray RD , Kim K , Umehara Y , Melmed S

Use of somatostatin (SRIF) analogs in acromegaly indicates greater lowering of IGF-I than predicted from GH reduction. Studies using hypophysectomized rats suggest a direct SRIF action on GH-induced IGF-I, however, interpretation is complicated by effects of SRIF on other hormonal axes. In isolated rat hepatocytes we showed SRIF and octreotide to have a direct inhibitory effect, via hepatic SSTRs, on GH-induced IGF-I production. GH (500 ng/ml) caused ~4 fold induction of IGF-I...

ea0029p1434 | Pituitary Clinical | ICEECE2012

Mortality rates in childhood and adult onset GH deficient patients enrolled in the Global Hypopituitary Control and Complications Study (HypoCCS)

Jung H. , Zimmermann A. , Mo D. , Robison L. , Erfurth E. , Melmed S. , Lamberts S. , Attanasio A.

Preliminary data suggested an increased mortality in a French cohort after childhood somatropin treatment compared to the French reference population1. This cohort included patients (pts) with idiopathic-isolated GH-deficiency (GHD), and a similar cohort is also under follow-up for adult GH-replacement in HypoCCS.We therefore assessed all-cause mortality rates (n/1000 person-years (PY), (95% CI), standardized to the age/gender structure...

ea0029p1463 | Pituitary Clinical | ICEECE2012

META-analysis on the effects of octreotide on tumor mass in acromegaly

Mazziotti G , Torri V , Spinello M , Floriani I , Melmed S , Giustina A

The long-acting somatostatin analogue octreotide is used either as an adjuvant or primary therapy to lower GH levels in patients with acromegaly and may also induce pituitary tumor shrinkage. However, inconclusive evidences in this respect have been produced by either single-center research paper or pooled analyses. Therefore, we performed a meta-analysis to thoroughly assess the current literature on the effect of octreotide on pituitary tumor shrinkage. A computerized Medlin...

ea0005p186 | Neuroendocrinology and Behaviour | BES2003

Effect of the novel somatostatin ligand, SOM230, on rat & human anterior pituitary hormone secretion

Murray R , Kim K , Ren S , Weckbecker G , Bruns C , Melmed S

The clinically available somatostatin (SRIF) analogues, octreotide and lanreotide, are the mainstay of treatment for patients with acromegaly in whom surgery has failed to adequately control GH and IGF-I levels or where surgery is contra-indicated. Both analogues exhibit selective high affinity for SRIF receptor subtype 2 (SSTR2). GH and TSH secretion are regulated by SSTR subtypes 2 & 5, with an additional effect on GH secretion via SSTR1. Prolactin is regulated by SSTR5 ...

ea0029p1783 | Thyroid cancer | ICEECE2012

Regulation of hPTTG expression and phosphorylation: autocrine interactions with growth factors in thyroid cells

Lewy G. , Ryan G. , Read M. , Fong J. , Seed R. , Sharma N. , Smith V. , Kwan P. , Stewart S. , Warfield A. , Melmed S. , Eggo M. , Franklyn J. , McCabe C. , Boelaert K.

Introduction: The human Pituitary Tumor Transforming Gene (hPTTG) is a phosphorylated proto-oncogene induced in multiple tumour types. hPTTG phosphorylation is mediated by cyclin-dependent kinase 2 (CDC2) and expression is regulated by specificity protein 1 (SP1). In thyroid cancer, hPTTG induces genetic instability and propagates growth through induction of growth factors (GFs).Methods: The interplay between hPTTG phosphorylation, SP1 regulation and GF ...